Safety and Efficacy Study of 10XB-101 in Adults With Bilateral Flank Adiposity

10xBio, LLC13 enrolled

Overview

The goal of this clinical trial is to test the safety and effectiveness of an injection study drug in decreasing bilateral flank adiposity. The main question it aims to answer is: •How safe and effective is the injection study drug in removing bilateral flank adiposity compared to a placebo? Participants will be: * Be given injections every month for 5 months over the right and left flanks. * Be asked to be seen in the clinic for 13 visits and 3 phone call visits during a duration of 1 year.

Fifteen subjects with bilateral flank adiposity will be enrolled across 1-3 sites in the USA.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Subcutaneous Fat Disorder

Interventions

10XB-101 Solution for Injection, 6.0%DRUG

The active drug (adipolytic) given as subcutaneous injection on either the right or left flank every 4 weeks for 20 weeks.

Placebo Solution for Injection (no active ingredient)DRUG

Placebo given as subcutaneous injection on either the right or left flank every 4 weeks for 20 weeks.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subject is a male or non-pregnant female 18 to 55 years old. * Subject has provided written informed consent. * Subject has qualifying fat evaluation and skin laxity scores on each right and left flanks. * Subject has had a stable body weight for the past 6 months prior to starting study. * Subject is willing to undergo test article injections as directed, comply with study instructions, and commit to all follow-up visits for the duration of the study. Exclusion Criteria: * Subject is pregnant, lactating, or is planning to become pregnant during the study. * Subject has loose skin in the right and left flank areas, unrepaired abdominal injury or defect, scars, tattoos, or other features that may interfere with evaluation of localized fat, in the opinion of the investigator. * Subject has any medical condition or taking medications that affects clotting and/or platelet function * Subject has a history of allergy or sensitivity to polidocanol or any of the other ingredients in the test articles.

Locations (2)

Site #01

Rolling Meadows, Illinois, United States

Site #02

New Brighton, Minnesota, United States

Outcomes

Primary Outcomes

Volumetric measurements

Change from Baseline until end of study. Volumetric measurements will be obtained on each right and left flanks thru a standard photographic assessment.

Time frame: 24 weeks after final injection treatment

Flank Skin Laxity Scale (FSLS)

Change from Baseline on each flank after final treatment. Flank Skin Laxity Scale (FSLS) is a 4 point scale, with a score of 0 for no skin folds, and a score of 3 for severe or worse skin folds.A higher score means a worse outcome.

Time frame: 24 weeks after final injection treatment

Clinician Global Impression of Change (CGIC)

Change from Baseline on each flank after final treatment. Clinician Global Impression of Change (CGIC) is a 7-point bi-directional scale with 1 as much improved and 7 as much worse.

Time frame: 24 weeks after final injection treatment

Patient Global Impression of Change (PGIC)

Change from Baseline on each flank after final treatment. Patient Global Impression of Change (PGIC) is a 7-point bi-directional scale with 1 as much improved and 7 as much worse.

Time frame: 24 weeks after final injection treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.